INDBInternet News Database 2.5 Updated 3 min ago · 393 sources Show or hide images Light or dark

Liso-Cel Plus Ibrutinib Yields Deep Remissions in R/R CLL

Save Like Comments Compare coverage

Summary

Researchers evaluate outcomes with ibrutinib plus liso-cel CAR T-cell therapy in patients with heavily pretreated relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Description from Medscape.

Who is covering this

  1. Medscape Center Factuality: Mostly factual US
    Liso-Cel Plus Ibrutinib Yields Deep Remissions in R/R CLL

    Researchers evaluate outcomes with ibrutinib plus liso-cel CAR T-cell therapy in patients with heavily pretreated relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Comments

Comments need JavaScript.